Showing results (31-40 of 64) with videos related to
Sort By:
Pageof 7
Tumori|November 6, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinomaRaffaele Ratta, Elena Verzoni, Alessia Mennitto, et al.Anticancer Research|August 21, 2003
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetateAntonia Martinetti, Nicoletta Zilembo, Leonardo Ferrari, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective StudyMattia Boeri, Massimo Milione, Claudia Proto, et al.The Pharmacogenomics Journal|February 5, 2019
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, et al.The Oncologist|March 13, 2020
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S TrialMaria Di Bartolomeo, Federica Morano, Alessandra Raimondi, et al.ESMO Open|March 10, 2020
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patientsGiovanni Crisafulli, Benedetta Mussolin, Andrea Cassingena, et al.Cancer Reports (Hoboken, N.J.)|November 7, 2025
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the LiteratureSimone Rota, Carolina Sciortino, Silvia Damian, et al.Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.Cancer|October 21, 2006
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III StudyEmilio Bajetta, Giuseppe Procopio, Laura Catena, et al.Pageof 7